--- title: T-CURX acquires Pantherna Therapeutics to accelerate clinical translation of its non-viral in vivo CAR-T strategies date: 2026-06-01T07:00:00Z modified: 2026-06-05T08:59:35Z permalink: "https://www.htgf.de/t-curx-acquires-pantherna-therapeutics/" type: post status: publish excerpt: "" wpid: 130443 categories: - News - Presse language: - Deutsch post_translations: - pll_6a183b4ae688f timestamp: 2026-06-05T08:59:35Z tags: - News - Presse - Deutsch - pll_6a183b4ae688f --- # T-CURX acquires Pantherna Therapeutics to accelerate clinical translation of its non-viral in vivo CAR-T strategies - T-CURX leverages Pantherna’s deep expertise and proprietary technologies in LNP-based delivery of mRNA and DNA vectors to advance T-CURX innovative in vivo CAR-T assets into clinical trials one year earlier - T-CURX’ proprietary and clinically validated transposon-based non-viral CAR-T technology is potentiated and de-risked by Pantherna’s proprietary PTXmRNA® and PTX-DLNP® platforms, enabling the expansion of in vivo CAR-T therapies beyond cancer indications - T-CURX’ acquisition of Pantherna builds on a successful prior technology collaboration and preclinical validation of their combined technologies Today, leading CAR-T company T-CURX announces the signing of a definitive agreement for the acquisition of Pantherna Therapeutics, a German biotechnology company specializing in mRNA engineering and lipid nanoparticle (LNP) delivery technologies. Pantherna will continue to operate as Pantherna Therapeutics as a wholly owned subsidiary of T-CURX. The complementary expertises and proprietary technologies of both companies will be leveraged to accelerate clinical translation of CAR-T strategies with a clear focus on clinical validation of in vivo CAR-T therapies. T-CURX is a Würzburg-headquartered private biotech company with an additional site in Munich with strong expertise, proprietary technologies and track record for clinical translation of non-viral, transposon-based CAR-T therapies for novel and differentiated targets. T-CURX is backed by private investors and an international syndicate of blue-chip Biotech investors led by Swiss BiomedVC. T-CURX closed a USD 20.5 million Series A financing round at the end of 2025. Pantherna was supported by a group of private investors and Germany-based High-Tech Gründerfonds (HTGF), who will become new shareholders of T-CURX. Financial terms of the transaction are not disclosed. > “With this acquisition, we are bringing together two highly complementary technology platforms and teams. We are taking a decisive step forward to accelerate the clinical development of differentiated, next-generation in vivo CAR-T therapies,” said **Ulf Grawunder, CEO and co-founder of T-CURX**. “Our strength in clinical translation of non-viral transposon-based CAR-T therapies combined with Pantherna’s proprietary mRNA and LNP-based delivery capabilities allows us to build an efficient engine to expedite clinical development of differentiated in vivo CAR-T assets in cancer, as well as in other indications.” > “Joining T-CURX is a natural evolution of our collaboration,” said **Ansgar Santel, CEO of Pantherna Therapeutics**. “This integration allows us to address both stable and transient cell engineering strategies based on powerful and proven proprietary platforms. We believe this positions us uniquely to efficiently drive CAR-T innovation forward for patients in need, particularly for in vivo CAR-T strategies across a broad range of therapeutic applications.” The combination of both companies positions T-CURX to become a leading next-generation CAR-T player, being the first European Biotech with both proprietary CAR-T and LNP-technologies under one roof, allowing integration of key capabilities across the full value chain from discovery to clinical development of CAR-T products. Post acquisition, the company will have a total headcount of 35 and will manage a collective portfolio of currently 16 patent families protecting the combined technologies and assets. --- **About T-CURX** T-CURX GmbH is a private, Würzburg & Munich based, German biotech company with a wholly owned subsidiary, Pantherna Therapeutics, in Hennigsdorf & Berlin, Germany, combining next-generation non-viral CAR-T and LNP-nucleic acid vector delivery technologies under one roof. T-CURX is financially backed by a syndicate of international VC investors and family offices from Germany and Switzerland, led by Swiss BiomedVC, with Bayernkapital (Germany), Highlight Capital (China) and i&iBio Fund (Czech Republic) as institutional co-investors. T-CURX has the vision to bring innovative CAR-T cell therapies based on cost-effective and highly scalable non-viral ex vivo and in vivo CAR-T strategies to more cancer patients in need of these effective cancer therapies. T-CURX was spun out of the laboratory of T-CURX’s co-founder Prof. Michael Hudecek at the University of Würzburg and is led by Ulf Grawunder, PhD, a seasoned serial entrepreneur as CEO, who is also one of the co-founders. For more information about T-CURX, visit the company’s website at: [www.t-curx.com](http://www.t-curx.com) **About Pantherna Therapeutics** Pantherna Therapeutics GmbH, a T-CURX company, is a biotech company from Hennigsdorf, Germany, with additional operations in Berlin, specializing in mRNA engineering and lipid nanoparticle (LNP) delivery technologies. Its proprietary PTXmRNA® and PTXΔLNP® platforms enable transient, controllable gene expression and targeted in vivo delivery of nucleic acids. Pantherna adds a crucial technology layer for potentiating T-CURX next-generation CAR-T therapies, further advancing ex vivo as well as future in vivo CAR-T strategies in oncology and also additional indications. For more information about Pantherna Therapeutics, visit the company’s website at [www.pantherna-therapeutics.com](http://www.pantherna-therapeutics.com)